Cardiovascular risk factors influence response to biological therapies in psoriasis - 15/07/15
Supported by a grant from the Spanish Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (FEDER). (grant PI 13/00680)–State Plan I+D+I 2013-2016. |
|
Disclosure: Dr Coto-Segura is an invited speaker for and receives grant/research support from Abbvie, Janssen-Cilag, Schering-Plough, Pfizer, Celgene, and Novartis. Drs Batalla, González-Fernández, González-Lara, Abalde, Salgado-Boquete, Queiro-Silva, and Coto have no conflicts of interest to declare. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was used in the production of this manuscript. |
Vol 73 - N° 2
P. 327-329 - août 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?